Hey we need revenue and lots of it to conduct al

Hey we need revenue and lots of it to conduct all the upcoming MANF trials...

As part of the option agreement, Amarantus has also agreed to engage Lonza via a long-term manufacturing services agreement (MSA) to produce ESS for human clinical trials and subsequent commercial distribution.


Amarantus estimates that the worldwide market for an effective treatment for Stage 3 and Stage 4 intractable severe burns exceeds $1 billion annually.


Current annual estimates in the United States show that more than $18B is spent on specialized care of patients with severe burn injuries.